How to choose the right tirzepatide alternative The best alternative depends entirely on why you need one
Specific Populations No clinically significant differences in semaglutide pharmacokinetics were observed based on age (18 years old), sex, race (White, Asian or Black or African American), ethnicity, body weight (40 to 188 kg), upper GI disease (i.e., chronic gastritis and/or gastroesophageal reflux disease), hepatic impairment (i.e., mild, moderate, severe based on the Child-Pugh system) and renal impairment (i.e., mild, moderate, severe, end staged renal disease)
But if accountability and structured support matter to you, Noom delivers
A 2023 study on tirzepatide found that participants who switched to a placebo after losing about 21% of their body weight in three years gained back about 14% over another year
Healthcare providers rely on patients to report all side effects, even those that seem minor, to get a complete picture of how the medication is affecting them